- Editor's PickNicole Sinclair•14 hours ago
Pharmaceutical giant Mylan (MYL), which has recently dominated headlines over the skyrocketing 400% price increase of its allergy drug, made the decision on Monday to introduce a lower-priced generic EpiPen competitor. Above-average price inflation on Mylan’s EpiPen franchise is certainly nothing new. As Raymond James’ Elliot Wilbur pointed out: If you Google the term “EpiPen price increase(s),” you get over 120,000 hits from 2011 to just prior to this latest story breaking.
- 24/7 Wall St.•9 hours ago
August 31, 2016: Here are four stocks trading with relatively heavy volume among 27 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 3 to 2 and Nasdaq decliners ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||78.21 x 200|
|Ask||78.45 x 500|
|Day's Range||77.58 - 78.60|
|52wk Range||77.58 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.88|
|Avg Vol (3m)||10,182,561|
|Dividend & Yield||1.88 (2.41%)|